Pneumocystis pneumonia in intensive care: clinical spectrum, prophylaxis patterns, antibiotic treatment delay impact, and role of corticosteroids. A French multicentre prospective cohort study.
Pneumocystis jirovecii
Adjunctive corticosteroid therapy
Delayed treatment
Intensive care
Mortality
Prophylaxis
Journal
Intensive care medicine
ISSN: 1432-1238
Titre abrégé: Intensive Care Med
Pays: United States
ID NLM: 7704851
Informations de publication
Date de publication:
03 Jun 2024
03 Jun 2024
Historique:
received:
29
02
2024
accepted:
10
05
2024
medline:
3
6
2024
pubmed:
3
6
2024
entrez:
3
6
2024
Statut:
aheadofprint
Résumé
Severe Pneumocystis jirovecii pneumonia (PJP) requiring intensive care has been the subject of few prospective studies. It is unclear whether delayed curative antibiotic therapy may impact survival in these severe forms of PJP. The impact of corticosteroid therapy combined with antibiotics is also unclear. This multicentre, prospective observational study involving 49 adult intensive care units (ICUs) in France was designed to evaluate the severity, the clinical spectrum, and outcomes of patients with severe PJP, and to assess the association between delayed curative antibiotic treatment and adjunctive corticosteroid therapy with mortality. We included 158 patients with PJP from September 2020 to August 2022. Their main reason for admission was acute respiratory failure (n = 150, 94.9%). 12% of them received antibiotic prophylaxis for PJP before ICU admission. The ICU, hospital, and 6-month mortality were 31.6%, 35.4%, and 40.5%, respectively. Using time-to-event analysis with a propensity score-based inverse probability of treatment weighting, the initiation of curative antibiotic treatment after 96 h of ICU admission was associated with faster occurrence of death [time ratio: 6.75; 95% confidence interval (95% CI): 1.48-30.82; P = 0.014]. The use of corticosteroids for PJP was associated with faster occurrence of death (time ratio: 2.48; 95% CI 1.01-6.08; P = 0.048). This study showed that few patients with PJP admitted to intensive care received prophylactic antibiotic therapy, that delay in curative antibiotic treatment was common and that both delay in curative antibiotic treatment and adjunctive corticosteroids for PJP were associated with accelerated mortality.
Identifiants
pubmed: 38829531
doi: 10.1007/s00134-024-07489-2
pii: 10.1007/s00134-024-07489-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Investigateurs
Auchabie Johann
(A)
Beuret Pascal
(B)
Darreau Cédric
(D)
Desmeulles Isabelle
(D)
Guervilly Christophe
(G)
Hong Tuan Ha Vivien
(HTH)
Jochmans Sébastien
(J)
Jozwiak Mathieu
(J)
Louis Guillaume
(L)
Navellou Jean-Christophe
(N)
Neuville Mathilde
(N)
Pichon Nicolas
(P)
Sagnier Anne
(S)
Schnell David
(S)
Informations de copyright
© 2024. The Author(s).
Références
Pereira-Díaz E, Moreno-Verdejo F, de la Horra C, Guerrero JA, Calderón EJ, Medrano FJ (2019) Changing trends in the epidemiology and risk factors of pneumocystis pneumonia in Spain. Front Public Health 7:275. https://doi.org/10.3389/fpubh.2019.00275
doi: 10.3389/fpubh.2019.00275
pubmed: 31637227
pmcid: 6788256
Grønseth S, Rogne T, Hannula R, Åsvold BO, Afset JE, Damås JK (2021) Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway. BMC Infect Dis 21:659. https://doi.org/10.1186/s12879-021-06144-1
doi: 10.1186/s12879-021-06144-1
pubmed: 34233631
pmcid: 8262122
Kolbrink B, Scheikholeslami-Sabzewari J, Borzikowsky C, von Samson- Himmelstjerna FA, Ullmann AJ, Kunzendorf U (2022) Schulte K (2022) Evolving epidemiology of pneumocystis pneumonia: findings from a longitudinal population-based study and a retrospective multi-center study in Germany. Lancet Reg Health Eur 18:100400. https://doi.org/10.1016/j.lanepe.2022.100400
doi: 10.1016/j.lanepe.2022.100400
pubmed: 35814339
pmcid: 9257643
Pates K, Periselneris J, Russell MD, Mehra V, Schelenz S, Galloway JB (2023) Rising incidence of Pneumocystis pneumonia: a population-level descriptive ecological study in England. J Infect 86:385–390. https://doi.org/10.1016/j.jinf.2023.02.014
doi: 10.1016/j.jinf.2023.02.014
pubmed: 36775251
Bienvenu A-L, Traore K, Plekhanova I, Bouchrik M, Bossard C, Picot S (2016) Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients. Int J Infect Dis 46:11–17
doi: 10.1016/j.ijid.2016.03.018
pubmed: 27021532
Ricciardi A, Gentilotti E, Coppola L, Maffongelli G, Cerva C, Malagnino V et al (2017) Infectious disease ward admission positively influences P. jiroveci pneumonia (PjP) outcome: a retrospective analysis of 116 HIV positive and HIV-negative immunocompromised patients. PLoS ONE 12:e0176881
doi: 10.1371/journal.pone.0176881
pubmed: 28505159
pmcid: 5432209
Cillóniz C, Dominedò C, Álvarez-Martínez MJ, Moreno A, García F, Torres A, Miro JM (2019) Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. Expert Rev Anti Infect Ther 17:787–801. https://doi.org/10.1080/14787210.2019.1671823
doi: 10.1080/14787210.2019.1671823
pubmed: 31550942
Elango K, Mudgal M, Murthi S, Yella PR, Nagrecha S, Srinivasan V, Sekar V, Koshy M, Ramalingam S, Gunasekaran K (2022) Trends in the epidemiology and outcomes of pneumocystis pneumonia among human immunodeficiency virus (HIV) hospitalizations. Int J Environ Res Public Health 19:2768. https://doi.org/10.3390/ijerph19052768
doi: 10.3390/ijerph19052768
pubmed: 35270461
pmcid: 8910294
Festic E, Gajic O, Limper AH, Aksamit TR (2005) Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features. Chest 128:573–579. https://doi.org/10.1378/chest.128.2.573
doi: 10.1378/chest.128.2.573
pubmed: 16100140
Monnet X, Vidal-Petiot E, Osman D, Hamzaoui O, Durrbach A, Goujard C, Miceli C, Bourée P, Richard C (2008) Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 12:R28. https://doi.org/10.1186/cc6806
doi: 10.1186/cc6806
pubmed: 18304356
pmcid: 2374632
Roux A, Canet E, Valade S, Gangneux-Robert F, Hamane S, Lafabrie A, Maubon D, Debourgogne A, Le Gal S, Dalle F, Leterrier M, Toubas D, Pomares C, Bellanger AP, Bonhomme J, Berry A, Durand-Joly I, Magne D, Pons D, Hennequin C, Maury E, Roux P, Azoulay É (2008) Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis 20:1490–1497. https://doi.org/10.3201/eid2009.131668
doi: 10.3201/eid2009.131668
Schmidt JJ, Lueck C, Ziesing S, Stoll M, Haller H, Gottlieb J, Eder M, Welte T, Hoeper MM, Scherag A, David S (2018) Clinical course, treatment and outcome of Pneumocystis pneumonia in immunocompromised adults: a retrospective analysis over 17 years. Crit Care 22:307. https://doi.org/10.1186/s13054-018-2221-8
doi: 10.1186/s13054-018-2221-8
pubmed: 30454031
pmcid: 6245758
Kim TO, Lee JK, Kwon YS, Kim YI, Lim SC, Kim MS, Kho BG, Park CK, Oh IJ, Kim YC, Park HY, Shin HJ (2021) Clinical characteristics and prognosis of patients with Pneumocystis jirovecii pneumonia without a compromised illness. PLoS ONE 16:e0246296. https://doi.org/10.1371/journal.pone.0246296
doi: 10.1371/journal.pone.0246296
pubmed: 33539407
pmcid: 7861382
Burghi G, Biard L, Roux A, Valade S, Robert-Gangneux F, Hamane S, Maubon D, Debourgogne A, Le Gal S, Dalle F, Leterrier M, Toubas D, Pomares C, Bellanger AP, Bonhomme J, Berry A, Iriart X, Durand-Joly I, Magne D, Pons D, Hennequin C, Maury E, Azoulay E, Lemiale V (2021) Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia. Eur J Clin Microbiol Infect Dis 40:1191–1198. https://doi.org/10.1007/s10096-020-04118-w
doi: 10.1007/s10096-020-04118-w
pubmed: 33411170
Ghembaza A, Vautier M, Cacoub P, Pourcher V, Saadoun D (2020) Risk factors and prevention of Pneumocystis jirovecii pneumonia in patients with autoimmune and inflammatory diseases. Chest 158:2323–2332. https://doi.org/10.1016/j.chest.2020.05.558
doi: 10.1016/j.chest.2020.05.558
pubmed: 32502592
Schmajuk G, Jafri K, Evans M, Shiboski S, Gianfrancesco M, Izadi Z, Patterson SL, Aggarwal I, Sarkar U, Dudley RA, Yazdany J (2019) Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Semin Arthritis Rheum 48:1087–1092. https://doi.org/10.1016/j.semarthrit.2018.10.018
doi: 10.1016/j.semarthrit.2018.10.018
pubmed: 30449650
Wolfe RM, Beekmann SE, Polgreen PM, Winthrop KL, Peacock JE Jr (2019) Practice patterns of pneumocystis pneumonia prophylaxis in connective tissue diseases: a survey of infectious disease physicians. Open Forum Infect Dis 6:ofz315. https://doi.org/10.1093/ofid/ofz315
doi: 10.1093/ofid/ofz315
pubmed: 31660399
pmcid: 6798249
Vieujean S, Moens A, Hassid D, Rothfuss K, Savarino EV, Vavricka SR, Reenaers C, Jacobsen BA, Allez M, Ferrante M, Rahier JF (2023) Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease—a case series. J Crohns Colitis 17:472–479. https://doi.org/10.1093/ecco-jcc/jjac153
doi: 10.1093/ecco-jcc/jjac153
pubmed: 36223253
Sierra CM, Daiya KC (2022) Prophylaxis for Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease: a systematic review. Pharmacotherapy 42:858–867. https://doi.org/10.1002/phar.2733
doi: 10.1002/phar.2733
pubmed: 36222368
pmcid: 9828113
Weyant RB, Kabbani D, Doucette K, Lau C, Cervera C (2021) Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother 22:1579–1592. https://doi.org/10.1080/14656566.2021.1915989
doi: 10.1080/14656566.2021.1915989
pubmed: 33870843
Alsayed AR, Al-Dulaimi A, Alkhatib M, Al Maqbali M, Al-Najjar MAA, Al- Rshaidat MMD (2022) A comprehensive clinical guide for Pneumocystis jirovecii pneumonia: a missing therapeutic target in HIV-uninfected patients. Expert Rev Respir Med 16:1167–1190. https://doi.org/10.1080/17476348.2022.2152332
doi: 10.1080/17476348.2022.2152332
pubmed: 36440485
Fragoulis GE, Dey M, Zhao S, Schoones J, Courvoisier D, Galloway J, Hyrich KL, Nikiphorou E (2022) Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. RMD Open 8:e002726. https://doi.org/10.1136/rmdopen-2022-002726
doi: 10.1136/rmdopen-2022-002726
pubmed: 36323488
pmcid: 9639159
Zhou S, Aitken SL (2023) Prophylaxis against Pneumocystis jirovecii pneumonia in adults. JAMA 330:182–183. https://doi.org/10.1001/jama.2023.9844
doi: 10.1001/jama.2023.9844
pubmed: 37358837
Li MC, Lee NY, Lee CC, Lee HC, Chang CM, Ko WC (2014) Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 47:42–47. https://doi.org/10.1016/j.jmii.2012.08.024
doi: 10.1016/j.jmii.2012.08.024
pubmed: 23063081
Fillâtre P, Revest M, Belaz S, Robert-Gangneux F, Zahar JR, Roblot F, Tattevin P (2016) Pneumocystose chez les patients immunodéprimés non infectés par le VIH [Pneumocystosis in non-HIV-infected immunocompromised patients]. Rev Med Interne 37(5):327–336. https://doi.org/10.1016/j.revmed.2015.10.002
doi: 10.1016/j.revmed.2015.10.002
pubmed: 26644039
Ramirez JA, Musher DM, Evans SE, Dela Cruz C, Crothers KA, Hage CA et al (2020) Treatment of community-acquired pneumonia in immunocompromised adults: a consensus statement regarding initial strategies. Chest 158:1896–1911. https://doi.org/10.1016/j.chest.2020.05.598
doi: 10.1016/j.chest.2020.05.598
pubmed: 32561442
Kovacs JA, Hiemenz JW, Macher AM, Stover D, Murray HW, Shelhamer J, Lane HC, Urmacher C, Honig C, Longo DL et al (1984) Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 100:663–671. https://doi.org/10.7326/0003-4819-100-5-663
doi: 10.7326/0003-4819-100-5-663
pubmed: 6231873
Asai N, Motojima S, Ohkuni Y, Matsunuma R, Nakashima K, Iwasaki T, Nakashita T, Otsuka Y, Kaneko N (2012) Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection. J Infect Chemother 18:898–905. https://doi.org/10.1007/s10156-012-0441-4
doi: 10.1007/s10156-012-0441-4
pubmed: 22692598
Song S, Zhang Y, Yu J, Xie C, Chen Y, Zhang X (2022) Time to trimethoprim/sulfamethoxazole initiation among patients with rheumatic disease complicated by Pneumocystis jirovecii pneumonia: impact on 90-day mortality. BMC Infect Dis 22:961. https://doi.org/10.1186/s12879-022-07940-z
doi: 10.1186/s12879-022-07940-z
pubmed: 36575406
pmcid: 9793549
Ewald H, Raatz H, Boscacci R, Furrer H, Bucher HC, Briel M (2015) Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. Cochrane Database Syst Rev 2015(4):006150. https://doi.org/10.1002/14651858.CD006150
doi: 10.1002/14651858.CD006150
Fujikura Y, Manabe T, Kawana A, Kohno S (2017) Adjunctive corticosteroids for Pneumocystis jirovecii pneumonia in non-HIV infected patients: a systematic review and meta-analysis of observational studies. Arch Bronconeumol 53:55–61. https://doi.org/10.1016/j.arbres.2016.06.016
doi: 10.1016/j.arbres.2016.06.016
pubmed: 27616706
Wieruszewski PM, Barreto JN, Frazee E, Daniels CE, Tosh PK, Dierkhising RA, Mara KC, Limper AH (2018) Early corticosteroids for pneumocystis pneumonia in adults without HIV are not associated with better outcome. Chest 154:636–644. https://doi.org/10.1016/j.chest.2018.04.026
doi: 10.1016/j.chest.2018.04.026
pubmed: 29705221
Inoue N, Fushimi K (2019) Adjunctive corticosteroids decreased the risk of mortality of non-HIV pneumocystis pneumonia. Int J Infect Dis 79:109–115. https://doi.org/10.1016/j.ijid.2018.12.001
doi: 10.1016/j.ijid.2018.12.001
pubmed: 30529109
Assal M, Lambert J, Chow-Chine L, Bisbal M, Servan L, Gonzalez F, de Guibert JM, Faucher M, Vey N, Sannini A, Mokart D (2021) Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with Pneumocystis jirovecii pneumonia: a propensity score analysis. PLoS ONE 16(4):e0250611. https://doi.org/10.1371/journal.pone.0250611
doi: 10.1371/journal.pone.0250611
pubmed: 33886692
pmcid: 8061944
Hosseini-Moghaddam SM, Kothari S, Humar A, Albasata H, Yetmar ZA, Razonable RR, Neofytos D, D’Asaro M, Boggian K, Hirzel C, Khanna N, Manuel O, Mueller NJ, Imlay H, Kabbani D, Tyagi V, Smibert OC, Nasra M, Fontana L, Obeid KM, Apostolopoulou A, Zhang SX, Permpalung N, Alhatimi H, Silverman MS, Guo H, Rogers BA, MacKenzie E, Pisano J, Gioia F, Rapi L, Prasad GVR, Banegas M, Alonso CD, Doss K, Rakita RM, Fishman JA (2023) Adjunctive glucocorticoid therapy for Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a multicenter cohort, 2015–2020. Am J Transpl S1600–6135(23):00858–00864. https://doi.org/10.1016/j.ajt.2023.11.003
doi: 10.1016/j.ajt.2023.11.003
Lagrou K, Chen S, Masur H, Viscoli C, Decker CF, Pagano L, Groll AH (2021) Pneumocystis jirovecii disease: basis for the revised EORTC/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus. Clin Infect Dis 72(Suppl 2):S114–S120. https://doi.org/10.1093/cid/ciaa1805
doi: 10.1093/cid/ciaa1805
pubmed: 33709126
pmcid: 8243279
Kanne JP, Yandow DR, Meyer CA (2012) Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol 198:W555-561
doi: 10.2214/AJR.11.7329
pubmed: 22623570
Fauchier T, Hasseine L, Gari-Toussaint M, Casanova V, Marty PM, Pomares C (2016) Detection of Pneumocystis jirovecii by quantitative PCR to differentiate colonization and pneumonia in immunocompromised HIV positive and HIV-negative patients. J Clin Microbiol 54(6):1487–1495. https://doi.org/10.1128/JCM.03174-15
doi: 10.1128/JCM.03174-15
pubmed: 27008872
pmcid: 4879311
Wei LJ (1992) The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med 11:1871–1879
doi: 10.1002/sim.4780111409
pubmed: 1480879
Desai RJ, Franklin JM (2019) Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ 367:l5657. https://doi.org/10.1136/bmj.l5657
doi: 10.1136/bmj.l5657
pubmed: 31645336
Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963. https://doi.org/10.1001/jama.270.24.2957
doi: 10.1001/jama.270.24.2957
pubmed: 8254858
Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710. https://doi.org/10.1007/BF01709751
doi: 10.1007/BF01709751
pubmed: 8844239
Stürmer T, Webster-Clark M, Lund JL, Wyss R, Ellis AR, Lunt M, Rothman KJ, Glynn RJ (2021) Propensity score weighting and trimming strategies for reducing variance and bias of treatment effect estimates: a simulation study. Am J Epidemiol 190:1659–1670. https://doi.org/10.1093/aje/kwab041
doi: 10.1093/aje/kwab041
pubmed: 33615349
pmcid: 8327194
Bruneel F, Veziris N, Chevret S, Wolff M, Bedos JP (2009) Retrospective review of Pneumocystis jirovecii pneumonia in a French intensive care unit (1994–2000). Int J STD AIDS 20:441–442. https://doi.org/10.1258/ijsa.2009.009107
doi: 10.1258/ijsa.2009.009107
pubmed: 19451339
Lemiale V, Debrumetz A, Delannoy A, Alberti C, Azoulay E (2013) Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res 14(1):87. https://doi.org/10.1186/1465-9921-14-87
doi: 10.1186/1465-9921-14-87
pubmed: 23981859
pmcid: 3765749
- Giacobbe DR, Dettori S, Di Pilato V, Asperges E, Ball L, Berti E, et al; JIR-ICU investigators (collaborators); Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESGCIP), and the Fungal Infection Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EFISG) (2023) Pneumocystis jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG. Crit Care 27:323. https://doi.org/10.1186/s13054-023-04608-1
Definition Task Force ARDS, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E et al (2012) Acute respiratory distress syndrome: the Berlin definition. JAMA 307:2526–2533
Desoubeaux G, Chesnay A, Mercier V, Bras-Cachinho J, Moshiri P, Eymieux S, De Kyvon MA, Lemaignen A, Goudeau A, Bailly É (2019) Combination of β-(1, 3)-D-glucan testing in serum and qPCR in nasopharyngeal aspirate for facilitated diagnosis of Pneumocystis jirovecii pneumonia. Mycoses 62:1015–1022. https://doi.org/10.1111/myc.12997
doi: 10.1111/myc.12997
pubmed: 31494981
Wettstein RB, Shelledy DC, Peters JI (2005) Delivered oxygen concentrations using low-flow and high-flow nasal cannulas. Respir Care 50:604–609
pubmed: 15871753
Boles JM, Bion J, Connors A, Herridge M, Marsh B, Melot C, Pearl R, Silverman H, Stanchina M, Vieillard-Baron A, Welte T (2007) Weaning from mechanical ventilation. Eur Respir J 29:1033–1056. https://doi.org/10.1183/09031936.00010206
doi: 10.1183/09031936.00010206
pubmed: 17470624